시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 췌장암 진단 시장 보고서(2025년)
Pancreatic Cancer Diagnostic Global Market Report 2025
상품코드 : 1824431
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

췌장암 진단 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 연평균 복합 성장률(CAGR) 8.8%로 성장할 전망이며, 63억 6,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 리퀴드 바이옵시의 진보, 표적 치료, 진단에서의 인공지능, 맞춤형 의료 접근법, 조기 발견 바이오마커, 네오애쥬번트 요법에 기인할 것으로 예측됩니다. 예측 기간 세계 동향에는 면역 요법 연구, 영상 기술의 진보, 수술의 혁신, 국제공동연구 이니셔티브, 빅데이터 분석의 통합 등이 포함됩니다.

향후 5년간의 성장률 8.8%라고 하는 예측은 전회 예측으로부터 0.1%라고 하는 미감소를 반영하고 있습니다. 이 감소는 주로 미국과 타국가 간 관세의 영향 때문입니다. 무역 마찰은 일본과 네덜란드에서 개발된 초음파 내시경(EUS) 시스템과 바이오마커 검사의 가격을 상승시켜 진단 지연과 소화기내과 비용 상승을 초래함으로써 미국에서 췌장암 조기 발견의 보급을 방해할 수 있습니다. 또한 상호관세와 무역 긴장 증가 및 제한 증가로 인한 세계경제와 무역에 대한 악영향으로 그 영향이 더욱 광범위해질 것으로 보입니다.

췌장암 진단 시장의 예상되는 성장은 췌장암의 유병률 증가에 의해 촉진될 것으로 예측됩니다. 췌장암은 췌장 조직에서 악성 세포의 개발을 특징으로 하며, 주로 흡연, 당뇨병, 만성 췌장염, 췌장암의 가족력, 췌장의 염증, 특정 유전 질환 등의 요인에 기인하여 증가하는 경향이 있습니다. 췌장암을 진단하는 것은 치료 정책을 결정하고, 암의 병기를 결정하고, 특정 종양의 특징을 확인하며, 치료 성적을 향상시키고, 환자의 치료를 최적화하기 위해 치료 접근법을 조정하는 데 매우 중요합니다. 미국 임상종양학회에 따르면 2023년에는 미국에서 6만 4,050명이 췌장암으로 진단된 것으로 평가되며, 여성에서는 8번째, 남성에서는 10번째로 많은 암이 됩니다. 췌장암의 신규 증례 발생률은 남녀 모두 연간 약 1%씩 증가하고 있습니다. 그 결과, 췌장암의 유병률 증가가 췌장암 진단 시장 확대의 중요한 요인이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Pancreatic cancer diagnostics involve the procedures and techniques employed to identify, classify, and stage pancreatic cancer, aiming to ascertain the condition's nature, assess disease severity, and guide treatment decisions. This diagnostic approach is commonly applied to address different types of pancreatic cancer, including adenocarcinoma, squamous cell carcinoma, and insulinoma.

The primary categories of pancreatic cancer diagnostic products comprise instruments, consumables, and services. Instruments refer to tools or devices utilized to perform specific tasks or achieve desired outcomes during diagnostic procedures, often involving the manipulation or examination of biological tissue. Various treatment modalities, such as surgery, chemotherapy, radiation therapy, and targeted therapy, are employed to address different types of pancreatic cancer, including exocrine, adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, colloid carcinoma, and endocrine. Diagnostic tests encompass a range of methods, including imaging tests, biopsies, blood tests, genomic tests, among others. These tests are utilized by diverse end-users, including hospitals, diagnostic centers, cancer research centers, academic institutes, ambulatory surgical centers, and other healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The pancreatic cancer diagnostic market research report is one of a series of new reports from The Business Research Company that provides pancreatic cancer diagnostic market statistics, including pancreatic cancer diagnostic industry global market size, regional shares, competitors with a pancreatic cancer diagnostic market share, detailed pancreatic cancer diagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the pancreatic cancer diagnostic industry. This pancreatic cancer diagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pancreatic cancer diagnostic market size has grown strongly in recent years. It will grow from $4.24 billion in 2024 to $4.54 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to growing genomic and molecular profiling, chemotherapy developments, radiation therapy refinements, research on pancreatic cancer genetics, awareness campaigns, and early detection efforts.

The pancreatic cancer diagnostic market size is expected to see strong growth in the next few years. It will grow to $6.36 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to liquid biopsy advancements, targeted therapies, artificial intelligence in diagnostics, personalized medicine approaches, early detection biomarkers, and neoadjuvant therapies. Major trends in the forecast period include immunotherapy research, advancements in imaging technologies, surgical innovations, global collaborative research initiatives, and integration of big data analytics.

The forecast of 8.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of early pancreatic cancer detection by inflating prices of endoscopic ultrasound (EUS) systems and biomarker tests developed in Japan and the Netherlands, resulting in delayed diagnoses and higher gastroenterology costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated growth in the pancreatic cancer diagnostic market is expected to be propelled by the increasing prevalence of pancreatic cancer. Pancreatic cancer, characterized by the development of malignant cells in the pancreas tissues, is on the rise, primarily attributed to factors such as smoking, diabetes, chronic pancreatitis, family history of pancreatic cancer, inflammation of the pancreas, and certain genetic disorders. Diagnosing pancreatic cancer is crucial for guiding treatment decisions, determining the cancer stage, identifying specific tumor characteristics, and tailoring treatment approaches to enhance outcomes and optimize patient care. According to the American Society of Clinical Oncology in 2023, it is estimated that 64,050 individuals in the United States will be diagnosed with pancreatic cancer, making it the eighth most common cancer in women and the tenth most common in men. The incidence of new cases of pancreatic cancer has been increasing by about 1% per year in both men and women. Consequently, the growing prevalence of pancreatic cancer is a significant driver behind the expansion of the pancreatic cancer diagnostic market.

The rising healthcare spending is contributing to the growth of the pancreatic cancer diagnostic market moving forward. Healthcare spending encompasses the total financial resources allocated to the healthcare sector within a specific region, country, or organization. This spending is directed toward pancreatic cancer diagnostics to enable early detection, accurate staging, and timely intervention, all of which aim to enhance patient outcomes and survival rates. For example, in November 2023, the Canadian Institute for Health Information reported that total health spending in Canada is expected to reach $344 billion in 2023, which equates to $8,740 per person. This represents a 2.8% increase from the previous year, when health spending grew by only 1.5% in 2022, highlighting a significant rebound in healthcare investment. Therefore, the increase in healthcare spending is driving the growth of the pancreatic cancer diagnostic market.

Product innovations stand out as a prominent trend gaining traction in the pancreatic cancer diagnostic market, with companies actively adopting innovative solutions to maintain their competitive positions. One noteworthy example is the introduction of Prestige Biopharma Limited's first-in-class PAUF-detecting diagnostic kit in March 2023. This diagnostic tool is designed for the early detection of pancreatic cancer, leveraging the identification of PAUF (Pancreatic Adenocarcinoma Upregulated Factor), a unique tumor-specific biomarker associated with early metastasis and prevalent in approximately 80% of pancreatic cancer cases. The innovative diagnostic technique exhibits high sensitivity and specificity in identifying PAUF, with preliminary studies indicating nearly a 1.9 times higher expression level of PAUF in the blood plasma of pancreatic cancer patients compared to healthy individuals, as reported by Prestige Biopharma's Innovative Discovery Center.

A focus on developing screening tests for pancreatic cancer is another notable strategy among major companies in the pancreatic cancer diagnostic market. Screening tests are designed to detect the presence of pancreatic cancer at an early, asymptomatic stage, enabling timely intervention and improving treatment outcomes. An example is the N-NOSE plus Pancreas test launched by Hirotsu Bio Science in December 2022. This test, marketed directly to consumers in Japan, utilizes the olfactory senses of nematodes, tiny worms, for pancreatic cancer detection.

In January 2024, Bristol-Myers Squibb (BMS), a US-based biopharmaceutical company, announced its acquisition of Mirati Therapeutics, Inc. for $4.8 billion. This strategic move bolsters BMS's portfolio by incorporating Mirati's innovative cancer treatment assets, particularly those aimed at pancreatic cancer. With this acquisition, BMS intends to utilize its global scale and resources to accelerate the delivery of more effective treatments to cancer patients. Mirati Therapeutics, Inc. is a US-based biotech firm specializing in pancreatic cancer diagnosis.

Major companies operating in the pancreatic cancer diagnostic market include Pfizer Inc., Hitachi Medical Corporation, F. Hoffmann-La Roche AG, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Becton Dickinson and Company, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Laboratory Corporation of America Holdings, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetics Inc., Canon Medical Systems Corporation, Biological Dynamics Inc., Berg LLC, Abcodia Ltd., Acobiom, Amplified Sciences LLC, Avant Diagnostics Inc., Axim Biotechnologies Inc., Alaunus Biosciences Inc., Advanced Marker Discovery SL, Anixa Diagnostics Corporation

North America was the largest region in the pancreatic cancer diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pancreatic cancer diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pancreatic cancer diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pancreatic cancer diagnostic market includes revenues earned by entities through computerized tomography (CT) scans, Magnetic resonance imaging (MRI), positron emission tomography (PET) scan, and ultrasound. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The pancreatic cancer diagnostic market consists of sales of tumor markers and drugs such as Abraxane, Afinitor, and Capecitabine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pancreatic Cancer Diagnostic Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pancreatic cancer diagnostic market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for pancreatic cancer diagnostic ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pancreatic cancer diagnostic market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Pancreatic Cancer Diagnostic Market Characteristics

3. Pancreatic Cancer Diagnostic Market Trends And Strategies

4. Pancreatic Cancer Diagnostic Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Pancreatic Cancer Diagnostic Growth Analysis And Strategic Analysis Framework

6. Pancreatic Cancer Diagnostic Market Segmentation

7. Pancreatic Cancer Diagnostic Market Regional And Country Analysis

8. Asia-Pacific Pancreatic Cancer Diagnostic Market

9. China Pancreatic Cancer Diagnostic Market

10. India Pancreatic Cancer Diagnostic Market

11. Japan Pancreatic Cancer Diagnostic Market

12. Australia Pancreatic Cancer Diagnostic Market

13. Indonesia Pancreatic Cancer Diagnostic Market

14. South Korea Pancreatic Cancer Diagnostic Market

15. Western Europe Pancreatic Cancer Diagnostic Market

16. UK Pancreatic Cancer Diagnostic Market

17. Germany Pancreatic Cancer Diagnostic Market

18. France Pancreatic Cancer Diagnostic Market

19. Italy Pancreatic Cancer Diagnostic Market

20. Spain Pancreatic Cancer Diagnostic Market

21. Eastern Europe Pancreatic Cancer Diagnostic Market

22. Russia Pancreatic Cancer Diagnostic Market

23. North America Pancreatic Cancer Diagnostic Market

24. USA Pancreatic Cancer Diagnostic Market

25. Canada Pancreatic Cancer Diagnostic Market

26. South America Pancreatic Cancer Diagnostic Market

27. Brazil Pancreatic Cancer Diagnostic Market

28. Middle East Pancreatic Cancer Diagnostic Market

29. Africa Pancreatic Cancer Diagnostic Market

30. Pancreatic Cancer Diagnostic Market Competitive Landscape And Company Profiles

31. Pancreatic Cancer Diagnostic Market Other Major And Innovative Companies

32. Global Pancreatic Cancer Diagnostic Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pancreatic Cancer Diagnostic Market

34. Recent Developments In The Pancreatic Cancer Diagnostic Market

35. Pancreatic Cancer Diagnostic Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기